Mr. Speaker, I hear the Prime Minister talking about a review of the prices charged and investments made by the pharmaceutical industry. It is also provided for in Bill C-91. We do not need to re-open that bill, a review is already planned. A body has been set up to monitor these things, so I put the question to the minister again.
Does the minister not agree that his intention to review the law has already hurt investment in research and development in Quebec and that his intended review has a much broader purpose than checking the prices of patented drugs or investments, which are already controlled by a body reporting to the Department of Health?